Table II.
CD44v9 and CD44std expression in tumors from patients with GBC.
| Factors | CD44v9
|
p-value | CD44std
|
p-value | ||
|---|---|---|---|---|---|---|
| Low (N=22) |
High (N=23) |
Low (N=22) |
High (N=23) |
|||
| Age | 71.1±10.7 | 69.2±11.5 | 0.566 | 70.9±12.0 | 68.0±8.2 | 0.450 |
| Sex | 0.928 | 0.702 | ||||
| Male | 6 (27%) | 6 (26%) | 10 (29%) | 2 (17%) | ||
| Female | 16 (73%) | 17 (74%) | 25 (71%) | 10 (83%) | ||
| CEA (ng/ml) | 4.1±3.1 | 12.9±20.9 | 0.032 | 7.2±11.9 | 13.2±22.7 | 0.243 |
| CA19-9 (U/ml) | 249.4±609.2 | 161.4±327.3 | 0.549 | 237.5±515.3 | 133.8±346.4 | 0.521 |
| Differentiation | 0.588 | 0.024 | ||||
| Well/Mod | 21 (95%) | 17 (89%) | 33 (97%) | 6 (67%) | ||
| Poor | 1 (5%) | 2 (11%) | 1 (3%) | 3 (33%) | ||
| pT | 0.850 | 0.261 | ||||
| 1–2 | 13 (62%) | 13 (59%) | 22 (65%) | 5 (45%) | ||
| 3–4 | 8 (38%) | 9 (41%) | 12 (35%) | 6 (55%) | ||
| pN | 0.790 | 0.733 | ||||
| Negative | 11 (55%) | 13 (59%) | 18 (56%) | 8 (67%) | ||
| Positive | 9 (45%) | 9 (41%) | 14 (44%) | 4 (33%) | ||
| M | 0.153 | 0.045 | ||||
| Negative | 16 (73%) | 12 (52%) | 24 (69%) | 4 (33%) | ||
| Positive | 6 (27%) | 11 (48%) | 11 (31%) | 8 (67%) | ||
| ly | 0.208 | 0.161 | ||||
| Negative | 11 (52%) | 6 (29%) | 16 (47%) | 2 (20%) | ||
| Positive | 10 (48%) | 15 (71%) | 18 (53%) | 8 (80%) | ||
| v | 0.059 | 0.074 | ||||
| Negative | 15 (71%) | 9 (43%) | 22 (65%) | 3 (30%) | ||
| Positive | 6 (29%) | 12 (57%) | 12 (35%) | 7 (70%) | ||